Moody Aldrich Partners LLC trimmed its position in Catalent Inc (NYSE:CTLT) by 32.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,485 shares of the company’s stock after selling 2,156 shares during the period. Moody Aldrich Partners LLC’s holdings in Catalent were worth $329,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in CTLT. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Catalent by 612.3% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,680 shares of the company’s stock worth $263,000 after acquiring an additional 4,023 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Catalent during the 4th quarter worth $219,000. Alliancebernstein L.P. lifted its holdings in shares of Catalent by 3.1% during the 4th quarter. Alliancebernstein L.P. now owns 272,614 shares of the company’s stock worth $15,348,000 after acquiring an additional 8,210 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Catalent by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 1,614,516 shares of the company’s stock worth $90,897,000 after acquiring an additional 59,104 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Catalent during the 4th quarter worth $83,479,000.
In related news, SVP Scott Gunther sold 2,824 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $72.00, for a total transaction of $203,328.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Aristippos Gennadios sold 8,325 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $73.00, for a total transaction of $607,725.00. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.05. Catalent had a net margin of 4.79% and a return on equity of 14.58%. The firm had revenue of $760.60 million for the quarter, compared to analysts’ expectations of $696.10 million. During the same quarter in the previous year, the company earned $0.49 earnings per share. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, equities research analysts forecast that Catalent Inc will post 1.6 earnings per share for the current year.
CTLT has been the subject of several recent research reports. Morgan Stanley boosted their price target on shares of Catalent from $75.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday. Royal Bank of Canada boosted their price target on shares of Catalent from $78.00 to $86.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. UBS Group boosted their price target on shares of Catalent from $77.00 to $97.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Argus initiated coverage on shares of Catalent in a research note on Thursday, June 25th. They issued a “buy” rating for the company. Finally, Deutsche Bank boosted their price target on shares of Catalent from $59.00 to $62.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $83.43.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Equity Income
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.